Gastroenterological safety of IL-17 inhibitors: a systematic literature review-Reference-Cited by-同舟云学术

Gastroenterological safety of IL-17 inhibitors: a systematic literature review

Published:2021-08-06 Issue:2 Volume:21 Page:223-239
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Caron Bénédicte¹,Jouzeau Jean-Yves²³,Miossec Pierre⁴,Petitpain Nadine⁵,Gillet Pierre³⁵,Netter Patrick³,Peyrin-Biroulet Laurent¹

Affiliation:

1. Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France

2. Department of Clinical Pharmacology and Toxicology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France

3. Ingénierie Moléculaire et Ingénierie Articulaire (Imopa), UMR-7365, CNRS, Faculté de Médecine, University of Lorraine and University Hospital of Nancy, Vandoeuvre-lès-Nancy, France

4. Department of Clinical Immunology and Rheumatology and the Immunogenomics and Inflammation Research Unit, University of Lyon, Hôpital Edouard Herriot, Lyon, France

5. Department of Clinical Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1960981

Reference211 articles.

1. The IL-23/IL-17 pathway in human chronic inflammatory diseases—new insight from genetics and targeted therapies

2. Targeting IL-17 and TH17 cells in chronic inflammation

3. Anonymous. Cosentyx. European Medicines Agency; September 17, 2018 [cited 2021 Apr 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx

4. Anonymous. Taltz. European Medicines Agency; September 17, 2018 [cited 2021 Apr 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/taltz

5. Anonymous. Kyntheum. European Medicines Agency; September 17, 2018 [cited 2021 Apr 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-17 signaling pathway: A potential therapeutic target for reducing skeletal muscle inflammation;Cytokine;2024-09

2. Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study;Doklady Biochemistry and Biophysics;2024-08-28

3. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29

4. Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study;Rheumatology Science and Practice;2023-12-31

5. Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology;Current Opinion in Rheumatology;2023-12-20